Pdt Partners, LLC Macrogenics Inc Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Pdt Partners, LLC holds 160,039 shares of MGNX stock, worth $489,719. This represents 0.05% of its overall portfolio holdings.

Number of Shares

160,039

Previous 110,751 44.5%

Holding current value

$489,719

Previous $470,000 11.91%

% of portfolio

0.05%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $147,864 - $273,548	49,288 Added 44.5%	160,039 $526,000
Q2 2024 Aug 15, 2024	BUY	$3.31 - $18.51 $366,585 - $2.05 Million	110,751 New	110,751 $470,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $212,183 - $443,425	-63,528 Reduced 57.72%	46,526 $312,000
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $230,930 - $400,483	-76,721 Reduced 41.08%	110,054 $381,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $104,512 - $464,035	46,450 Added 33.1%	186,775 $551,000
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $1.14 Million - $2.37 Million	140,325 New	140,325 $1.24 Million
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $1.46 Million - $2.12 Million	-74,014 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $466,926 - $811,936	22,788 Added 44.49%	74,014 $1.99 Million
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $432,478 - $756,096	-22,774 Reduced 30.78%	51,226 $1.63 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $693,789 - $887,960	28,100 Added 61.22%	74,000 $1.86 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $238,680 - $1.34 Million	45,900 New	45,900 $1.28 Million

Others Institutions Holding MGNX

# of Institutions

133

Shares Held

55.5M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $188M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account